Kesimpta 20 mg solution for injection in pre-filled pen, Kesimpta 20 mg solution for injection in pre-filled pen
COMB157G23101
Phase 3 small_molecule active
Quick answer
Kesimpta 20 mg solution for injection in pre-filled pen, Kesimpta 20 mg solution for injection in pre-filled pen for relapsing multiple sclerosis (RMS) is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- relapsing multiple sclerosis (RMS)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active